Another 293,000 Americans filed claims, 320,000 expected
Kelowna, British Columbia –News Direct– Lexaria Bioscience Corp.
DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes
Kelowna, British Columbia – TheNewswire – October 13, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that its recent oral tetrahydrocannabinol (“THC”) absorption study THC-A21-1 revealed that DehydraTECHTM-THC delivered via oral ingestion required only 15 minutes to deliver THC levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls.
During the study DehydraTECH-THC delivered more THC into bloodstream than the industry standard medium chain triglyceride (“MCT” or “coconut oil”) based control formulation from the 2-minute mark onwards, then dropped rapidly to the same level as the MCT control by the 6-hour mark.
Click Image To View Full Size
According to Harvard Medical School, the most common use for medical cannabis in the US is for the control of pain. Chronic pain is associated with nerve disorders and multiple sclerosis, and users are frequently cited as responding to a cannabis treatment program, without the highly addictive or sedating effects of opiates. Lexaria’s investigation of enhanced delivery characteristics of THC utilizing DehydraTECH technology is focused on medical applications.
Key pharmacokinetic (“PK”) findings from the study are tabulated below demonstrating statistically significant improvements in peak and total THC delivery (i.e., maximum concentration or Cmax and total area under the curve up to the point of the last measurement or AUClast respectively):
DehydraTECH-THC Cmax* % Improvement
MCT Control THC
AUClast** % Improvement
MCT (Coconut Oil) Control THC
178.6 ± 81.1
84.7 ± 43.9
539.2 ± 190.9
274.4 ± 106.9
“The cannabis industry continues to use outdated formulations and processes that ignore the needs of modern THC users,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “THC users today include recreational, medicinal and pharmaceutical users, all of whom need technology that doesn’t rely on harmful delivery methods such as smoking but still provides rapid onset and high bioavailability which common oral formats do not offer. Our study findings demonstrated rapid delivery, increased overall THC delivery, and higher brain tissue delivery; all of which is consistent with the wants and needs of THC customers.”
DehydraTECH processing continues to prove its ability to deliver drugs more effectively not just into the bloodstream, but also into brain tissue. Only two time-points were selected to collect brain tissue absorption samples, meaning blood concentration levels likely had peaked much earlier, but DehydraTECH-THC brain tissue levels were effectively twice as high as the MCT controls, mirroring what was seen with the blood level readings achieved during the study:
Coconut-Oil Control THC
121.0 ± 92.6
59.6 ± 20.5
14.4 ± 10.3
6.9 ± 5.2
About Study THC-A21-1
Study THC-A21-1 was performed by a leading, independent testing laboratory. Blood samples for 20 male Sprague Dawley rats (two groups of 10) are represented in the graph above taken at intervals of 2, 4, 6, 8, 12, 15, 30, 45, and 60 minutes, and at 2, 4 and 6 hours. Brain tissues were collected at 8 and 24 hours.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Phone: 250-765-6424, ext 202
View source version on newsdirect.com: https://newsdirect.com/news/lexarias-technology-proven-to-deliver-oral-thc-more-effectively-987509499
Moderna's (NASDAQ: MRNA) stock has seen better days. Shares of the coronavirus vaccine giant have dropped 30% over the past month. Now, investors have turned their attention to something else: A regulatory meeting that could determine whether Moderna's booster candidate reaches the market in the coming days.
Late last month, Pfizer (NYSE: PFE) announced that its drug, abrocitinib, was approved by Japan's Ministry of Health, Labour and Welfare (MHLW) as a treatment for patients 12 years old and up with moderate to severe atopic dermatitis or eczema. Japan's regulatory approval of abrocitinib under its trade name of Cibinqo came just weeks after approval by the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for adults and adolescents with moderate to severe eczema. Let's dig into why the MHLW approved the drug for its eczema indication, as well as its sales potential and what it means for Pfizer.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has initiated dosing in a bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.
Analysts were split Wednesday as they compared Crispr's gene-edited cancer drug to Allogene's — but CRSP stock tumbled as ALLO stock popped.
Is AbbVie stock a buy as shares make a comeback on promising news for its drugs, Skyrizi and Rinvoq, in inflammatory conditions?
Take action instead of just crossing off the days until you turn 65.
The FDA authorized marketing of the first e-cigarette products, and several others are under review.
Shares of Regeneron Pharmaceuticals Inc. gained 2.7% in premarket trading on Thursday after the company said the Food and Drug Administration accepted its application for approval of its monoclonal antibody treatment for non-hospitalized COVID-19 patients and as a prophylaxis for some people who have been exposed to the virus. The FDA said it will decide whether to approve the therapy by April 13 based on the priority review designation it granted to the application. It plans to hold an advisory
(Bloomberg) — Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.Most Read from BloombergHow France Turned the Humble Roundabout Into a Showcase for ArtWhat the Front Line of the U.S. Abortion Fight in Kentucky Looks Like NowWhat Comes After GE’s 129 Years of Greenhouse GasThey Invented the Must-Have Instrument for the
Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.
"People with body dysmorphia do not really see themselves as the world sees them," one expert tells Yahoo Life.
Growth stocks can be a thing of beauty. The trick, if you will, is to suss out growth stocks that won't rot on the vine, so to speak. While both of these biotech stocks have more than doubled in value in the past three years, I believe each of these healthcare equities still has a lot of room to run in 2022 and beyond.
Shares of life sciences company Quanterix (NASDAQ: QTRX) are up 14% as of 11:30 a.m. EDT today after the Food and Drug Administration granted breakthrough status to its blood test for a biomarker of Alzheimer's disease. Tau is a protein that stabilizes microtubules in the neurons of the central nervous system. In Alzheimer's disease, tau detaches from the microtubules and tangles.
Two of the biggest employers in Texas, American Airlines Group and Southwest Airlines Co., said they would not follow the executive order signed by Gov. Greg Abbott on Monday banning COVID-19 vaccine mandates in the Lone Star state, because as federal contractors, they are bound to comply with President Joe Biden's requirement.
Jonathan Moore, one of the first employees of Vertex Pharmaceuticals Inc. and a key scientist behind the company's renowned cystic fibrosis drugs, has a new venture called Rectify Pharmaceuticals.
"Anyone who exists in a fat body has a horror story about a time they were simply trying to enjoy food in public."
New Cerner Corp. CEO Dr. David Feinberg extols the progress made in health care, but he notes that patients and providers still must deal with significant hassles, something he intends to have the North Kansas City health IT company ameliorate.
While vaccinated people still remain heavily protected against severe COVID cases, it's become clear over the past few months that protection against any infection may not be as strong as it once was. Breakthrough COVID cases have hit millions of people in the U.S., and while the vast majority are mild, you still probably want to know how protected you are against getting sick. Recent research has shown that time, age, and the Delta variant have all played a role in these breakthrough cases, but
It's often hard to tell if a new medication is working initially. In the first few days of using a new prescription, you may not notice significant improvements in the condition you're trying to treat. However, in the case of one common prescription, you may find yourself not only noticing changes in your condition, but serious health issues, as well. Now, the U.S. Food&Drug Administration (FDA) is telling customers to stop using this popular medication immediately. Read on to discover if your m
Millions of people in the U.S. are already receiving booster shots, after the Food and Drug Administration (FDA) approved an additional dose of Pfizer for certain groups in late September. Now, the agency is scheduled to meet on Oct. 14 to discuss and vote on a third Moderna shot. Two days ahead of that meeting, the FDA published a report evaluating the safety and efficacy of Moderna's booster dose. The report utilizes data on booster shot side effects from a trial of nearly 200 recipients who w